Bio-Techne has officially opened a state-of-the-art manufacturing facility in Bristol, United Kingdom, marking a significant expansion of the company’s global footprint in the rapidly evolving cell therapy market. The 10,000-square-foot site is purpose-built to produce Good Manufacturing Practice (GMP)-grade small molecules, a critical component for developers looking to transition from early-stage clinical research to full-scale commercialization.
The new Bristol facility is equipped with high-specification infrastructure to meet the rigorous regulatory standards required for advanced therapy manufacturing. The site features five ISO-8 multifunctional cleanrooms and two ISO-7 cleanrooms, specifically designed to ensure the reproducibility and quality of materials essential for cell therapy applications. By establishing these capabilities in the UK, Bio-Techne aims to bolster its supply chain reliability, providing developers with the high-quality reagents and tools necessary to overcome the manufacturing bottlenecks that frequently plague the biotech industry.
This strategic expansion complements Bio-Techne’s existing operational network, which includes extensive recombinant protein manufacturing and established GMP capabilities at the company’s headquarters in Minnesota. Together, these locations form a robust global framework designed to support the scalability of next-generation therapies.
“Success increasingly depends on the ability to manufacture therapies consistently and at scale,” said Kim Kelderman, President and CEO of Bio-Techne. “Our investment in Bristol demonstrates Bio-Techne’s commitment to providing customers with necessary GMP materials, manufacturing expertise, and supply chain reliability.”
The opening of the Bristol plant arrives at a pivotal moment in the company’s history, occurring under the shadow of a major structural shift. The facility is now fully operational as Bio-Techne moves closer to completing its $11 billion acquisition by the German life sciences giant, Merck KGaA, Darmstadt, Germany.
First announced in June 2026, the acquisition represents a massive consolidation in the life sciences sector. Bio-Techne shareholders officially voted to approve the transaction in September, signaling strong support for the merger. With regulatory milestones currently being cleared, the deal is expected to close in late 2026 or early 2027.
Industry analysts note that the Bristol facility will likely serve as a key asset within the combined entity. By integrating Bio-Techne’s specialized small molecule manufacturing with Merck KGaA’s expansive global reach and existing technology platforms, the combined company is poised to dominate the supply chain for therapy developers.
For now, the Bristol team is focused on hitting the ground running. The facility is already manufacturing GMP-grade materials for a growing roster of global clients, further cementing Bio-Techne’s role as an essential partner in the quest to bring the next generation of life-saving cell therapies to patients worldwide.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
